Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of MIV-210 in antiretroviral treatment experienced HIV-1 infected subjects
2005-001738-34Phase 2Completed
- Sponsor
- Medivir
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MIV-210 in Human immunodeficiency virus infection type 1, sponsored by Medivir. Primary endpoint: Change in plasma HIV RNA. Started May 2005; status: completed.
02
Drugs
MIV-210
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001738-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001738-34.